Karus Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Liquidation

Karus Therapeutics General Information

Description

Developer of small molecule drugs designed to promote cancer therapies. The company's small-molecule drugs combine targeted therapy with immunotherapeutic activity for the effective treatment of a diverse range of solid and haematological cancers through oral small-molecule cancer drugs, enabling users to treat immune and inflammatory disorders as well as a diverse range of tumours.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Building 173, The Innovation Centre
  • Harwell Campus, Oxfordshire
  • Didcot OX11 0QG
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • Building 173, The Innovation Centre
  • Harwell Campus, Oxfordshire
  • Didcot OX11 0QG
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Bankruptcy: Liquidation 18-Dec-2023 Completed Bankruptcy: Liquidation
11. Secondary Transaction - Private 01-Oct-2021 Completed Generating Revenue
10. Later Stage VC 20-Apr-2021 Completed Generating Revenue
9. Later Stage VC 06-May-2016 Completed Generating Revenue
8. Later Stage VC 21-Sep-2015 Completed Generating Revenue
7. Later Stage VC 04-Feb-2014 Completed Generating Revenue
6. Later Stage VC (Series B) 07-Jun-2012 Completed Generating Revenue
5. Later Stage VC 04-May-2010 Completed Generating Revenue
4. Later Stage VC 06-Apr-2009 $1.45M $3.99M Completed Startup
3. Early Stage VC 01-Jul-2007 $1.7M $2.54M Completed Startup
To view Karus Therapeutics’s complete valuation and funding history, request access »

Karus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series B
Series B
Ordinary
Ordinary
Ordinary
Ordinary 177 $0.013791 $271.59 $271.59 1x $271.59 0.02%
Ordinary 6,000 $0.013791 $103.43 $103.43 1x $103.43 0.55%
To view Karus Therapeutics’s complete cap table history, request access »

Karus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule drugs designed to promote cancer therapies. The company's small-molecule drugs combine targe
Biotechnology
Didcot, United Kingdom
6 As of 2022

Bengaluru, India
 

Indianapolis, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karus Therapeutics Competitors (123)

One of Karus Therapeutics’s 123 competitors is Biocon Biologics, a Formerly PE-Backed company based in Bengaluru, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Biologics Formerly PE-Backed Bengaluru, India
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Genentech Formerly VC-backed South San Francisco, CA
Attune Pharmaceuticals Venture Capital-Backed New York, NY
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
You’re viewing 5 of 123 competitors. Get the full list »

Karus Therapeutics Patents

Karus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202106860-D0 Histone deacrtylase inhibitors Inactive 13-May-2021
GB-202009784-D0 Histone deacetylase inhibitors Inactive 26-Jun-2020
GB-201912813-D0 Histone deacetylase inhibitors Inactive 05-Sep-2019
GB-201909466-D0 Compounds for treating cancer Inactive 01-Jul-2019
GB-201909468-D0 Compounds for treating cancer Inactive 01-Jul-2019 A61K31/5386
To view Karus Therapeutics’s complete patent history, request access »

Karus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karus Therapeutics FAQs

  • When was Karus Therapeutics founded?

    Karus Therapeutics was founded in 2004.

  • Where is Karus Therapeutics headquartered?

    Karus Therapeutics is headquartered in Didcot, United Kingdom.

  • What is the size of Karus Therapeutics?

    Karus Therapeutics has 6 total employees.

  • What industry is Karus Therapeutics in?

    Karus Therapeutics’s primary industry is Biotechnology.

  • Is Karus Therapeutics a private or public company?

    Karus Therapeutics is a Private company.

  • What is Karus Therapeutics’s current revenue?

    The current revenue for Karus Therapeutics is .

  • How much funding has Karus Therapeutics raised over time?

    Karus Therapeutics has raised $101M.

  • Who are Karus Therapeutics’s competitors?

    Biocon Biologics, Apexian Pharmaceuticals, Genentech, Attune Pharmaceuticals, and Aro Biotherapeutics are some of the 123 competitors of Karus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process